On the heels of the U.K. spending watchdog's rejection of Roche's ($RHHBY) skin cancer drug Zelboraf, the National Institute for Health and Clinical Excellence (NICE) has denied the Swiss drugmaker's Avastin to combat late-stage breast cancer.
Roche ($RHHBY) has again had a cancer treatment rejected by the U.K.'s cost containment agency. This time, the National Institute for Health and Clinical Excellence (NICE) said that while using Avastin with the chemotherapy treatment Xeloda delayed the progression of breast cancer than chemotherapy alone, there was insufficient evidence that patients ultimately lived longer.
In drug development circles the U.K.'s NICE is known as something of a Grinch. Developers routinely spend huge sums getting their drugs through the regulatory process only to have the agency bat them down as too expensive.
With drugmakers flocking to lucrative drug markets for specialty care drugs, the bar has risen to get reimbursement and physician uptake of the expensive products. But there are ways to hedge bets in the specialty care game. We covered several such strategies during a panel I moderated at the 2012 BIO International Convention called "Are Healthcare Reimbursement Policies a Barrier to Specialty Care Treatment?" The easy answer to this question is "yes."
The refusal by NICE on Friday to recommend that the U.K. health system buy Roche's ($RHHBY) melanoma drug Zelboraf illustrates why the debate over expensive end-of-life cancer drugs is not going to die.
Roche ($RHHBY) thinks the U.K.'s NICE is not playing nice. With its rejection today of Roche's melanoma treatment Zelboraf, the drug overseer has now snubbed 9 of 10 end-of-life cancer drugs, Reuters reports.
The U.K.'s cost-effectiveness watchdog is having second thoughts about Amgen's new bone drug.
British media are reporting on a study suggesting that U.K. patients twiddle their thumbs for up to 9 years as the National Institute for Health and Clinical Excellence deliberates over new products.
Britain's cost-effectiveness watchdog reversed its decision against the Johnson & Johnson prostate cancer pill, thanks to the company's new discount offer.
After an initial draft guidance rejecting the lung cancer treatment, the National Institute for Health and Clinical Excellence now says Tarceva should be available as a first-line treatment.